🚀 VC round data is live in beta, check it out!
Shield Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Shield Therapeutics and similar public comparables like XSpray Pharma, NeOnc, Immunic, Oncolytics Biotech and more.
Shield Therapeutics Overview
About Shield Therapeutics
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
Founded
2015
HQ
Employees
77
Website
Sectors
Financials (LTM)
EV
$151M
Shield Therapeutics Financials
Shield Therapeutics reported last 12-month revenue of $58M and negative EBITDA of ($6M).
In the same LTM period, Shield Therapeutics generated $26M in gross profit, ($6M) in EBITDA losses, and had net loss of ($13M).
Revenue (LTM)
Shield Therapeutics P&L
In the most recent fiscal year, Shield Therapeutics reported revenue of $32M and EBITDA of ($21M).
Shield Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $58M | XXX | $32M | XXX | XXX | XXX |
| Gross Profit | $26M | XXX | $15M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | ($6M) | XXX | ($21M) | XXX | XXX | XXX |
| EBITDA Margin | (10%) | XXX | (66%) | XXX | XXX | XXX |
| EBIT Margin | (12%) | XXX | (71%) | XXX | XXX | XXX |
| Net Profit | ($13M) | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | (23%) | XXX | (84%) | XXX | XXX | XXX |
| Net Debt | — | — | $20M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Shield Therapeutics Stock Performance
Shield Therapeutics has current market cap of $133M, and enterprise value of $151M.
Market Cap Evolution
Shield Therapeutics' stock price is $0.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $151M | $133M | -1.9% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialShield Therapeutics Valuation Multiples
Shield Therapeutics trades at 2.6x EV/Revenue multiple, and (27.1x) EV/EBITDA.
EV / Revenue (LTM)
Shield Therapeutics Financial Valuation Multiples
As of April 18, 2026, Shield Therapeutics has market cap of $133M and EV of $151M.
Equity research analysts estimate Shield Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shield Therapeutics has a P/E ratio of (10.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $133M | XXX | $133M | XXX | XXX | XXX |
| EV (current) | $151M | XXX | $151M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | (27.1x) | XXX | (7.1x) | XXX | XXX | XXX |
| EV/EBIT | (22.0x) | XXX | (6.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.8x | XXX | 10.1x | XXX | XXX | XXX |
| P/E | (10.1x) | XXX | (4.9x) | XXX | XXX | XXX |
| EV/FCF | (33.1x) | XXX | (16.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Shield Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Shield Therapeutics Margins & Growth Rates
Shield Therapeutics' revenue in the last 12 month grew by 49%.
Shield Therapeutics' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Shield Therapeutics' rule of 40 is 59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shield Therapeutics' rule of X is 139% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Shield Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | (10%) | XXX | (66%) | XXX | XXX | XXX |
| EBITDA Growth | (264%) | XXX | (55%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 59% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 139% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 36% | XXX | 74% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 33% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 117% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Shield Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shield Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XSpray Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| NeOnc | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunic | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncolytics Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| AN2 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shield Therapeutics M&A Activity
Shield Therapeutics acquired XXX companies to date.
Last acquisition by Shield Therapeutics was on XXXXXXXX, XXXXX. Shield Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Shield Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialShield Therapeutics Investment Activity
Shield Therapeutics invested in XXX companies to date.
Shield Therapeutics made its latest investment on XXXXXXXX, XXXXX. Shield Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Shield Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Shield Therapeutics
| When was Shield Therapeutics founded? | Shield Therapeutics was founded in 2015. |
| Where is Shield Therapeutics headquartered? | Shield Therapeutics is headquartered in United Kingdom. |
| How many employees does Shield Therapeutics have? | As of today, Shield Therapeutics has over 77 employees. |
| Who is the CEO of Shield Therapeutics? | Shield Therapeutics' CEO is Karl Anders Lundstrom. |
| Is Shield Therapeutics publicly listed? | Yes, Shield Therapeutics is a public company listed on London Stock Exchange. |
| What is the stock symbol of Shield Therapeutics? | Shield Therapeutics trades under STX ticker. |
| When did Shield Therapeutics go public? | Shield Therapeutics went public in 2016. |
| Who are competitors of Shield Therapeutics? | Shield Therapeutics main competitors are XSpray Pharma, NeOnc, Immunic, Oncolytics Biotech. |
| What is the current market cap of Shield Therapeutics? | Shield Therapeutics' current market cap is $133M. |
| What is the current revenue of Shield Therapeutics? | Shield Therapeutics' last 12 months revenue is $58M. |
| What is the current revenue growth of Shield Therapeutics? | Shield Therapeutics revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of Shield Therapeutics? | Current revenue multiple of Shield Therapeutics is 2.6x. |
| Is Shield Therapeutics profitable? | No, Shield Therapeutics is not profitable. |
| What is the current EBITDA of Shield Therapeutics? | Shield Therapeutics has negative EBITDA and is not profitable. |
| What is Shield Therapeutics' EBITDA margin? | Shield Therapeutics' last 12 months EBITDA margin is (10%). |
| What is the current EV/EBITDA multiple of Shield Therapeutics? | Current EBITDA multiple of Shield Therapeutics is (27.1x). |
| What is the current FCF of Shield Therapeutics? | Shield Therapeutics' last 12 months FCF is ($5M). |
| What is Shield Therapeutics' FCF margin? | Shield Therapeutics' last 12 months FCF margin is (8%). |
| What is the current EV/FCF multiple of Shield Therapeutics? | Current FCF multiple of Shield Therapeutics is (33.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.